Marina Biotech Announces Worldwide Exclusive Licensing Agreement With Monsanto
News Jul 02, 2012
Marina Biotech, Inc. has announced that it has entered into an exclusive licensing agreement with Monsanto Company for Marina Biotech's delivery and chemistry technologies. Terms of the agreement were not disclosed.
"We are pleased to enter into this agreement with Monsanto, a global leader in agriculture and crop sciences," stated J. Michael French, President and Chief Executive Officer of Marina Biotech.
French continued, "Over the last several years, we have been focused on bringing together novel chemistry and delivery technologies necessary to broadly apply our discovery platform across the life sciences sector. We view this license as yet another important validation of this platform and we look forward to a strong and growing relationship with Monsanto."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.